Nek­tar up­dates PhIb atopic der­mati­tis da­ta amid Lil­ly suit; Cure, Frac­etat join forces on AAV plat­form

Nek­tar Ther­a­peu­tics has un­veiled up­dat­ed re­sults from a Phase Ib tri­al of its atopic der­mati­tis (AD) can­di­date, rezpe­galdesleukin, in the midst of a case against …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER